Amphastar Pharmaceuticals AMPH Stock
Amphastar Pharmaceuticals Price Chart
Amphastar Pharmaceuticals AMPH Financial and Trading Overview
Amphastar Pharmaceuticals stock price | 24.07 USD |
Previous Close | 47.94 USD |
Open | 48.43 USD |
Bid | 0 USD x 1100 |
Ask | 0 USD x 3100 |
Day's Range | 48.43 - 52.82 USD |
52 Week Range | 26.76 - 52.85 USD |
Volume | 1.06M USD |
Avg. Volume | 415.91K USD |
Market Cap | 2.52B USD |
Beta (5Y Monthly) | 0.76514 |
PE Ratio (TTM) | 28.540983 |
EPS (TTM) | 3.13 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 50.5 USD |
AMPH Valuation Measures
Enterprise Value | 2.18B USD |
Trailing P/E | 28.540983 |
Forward P/E | 18.390846 |
PEG Ratio (5 yr expected) | 0.77 |
Price/Sales (ttm) | 4.861457 |
Price/Book (mrq) | 4.5872126 |
Enterprise Value/Revenue | 4.209 |
Enterprise Value/EBITDA | 15.046 |
Trading Information
Amphastar Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 0.76514 |
52-Week Change | 65.70% |
S&P500 52-Week Change | 20.43% |
52 Week High | 52.85 USD |
52 Week Low | 26.76 USD |
50-Day Moving Average | 42.17 USD |
200-Day Moving Average | 33.54 USD |
AMPH Share Statistics
Avg. Volume (3 month) | 415.91K USD |
Avg. Daily Volume (10-Days) | 498.11K USD |
Shares Outstanding | 48.27M |
Float | 37.67M |
Short Ratio | 4.74 |
% Held by Insiders | 22.04% |
% Held by Institutions | 62.57% |
Shares Short | 1.88M |
Short % of Float | 6.14% |
Short % of Shares Outstanding | 3.89% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 17.96% |
Operating Margin (ttm) | 23.00% |
Gross Margin | 51.45% |
EBITDA Margin | 27.97% |
Management Effectiveness
Return on Assets (ttm) | 10.00% |
Return on Equity (ttm) | 18.12% |
Income Statement
Revenue (ttm) | 518.64M USD |
Revenue Per Share (ttm) | 10.69 USD |
Quarterly Revenue Growth (yoy) | 16.30% |
Gross Profit (ttm) | 248.86M USD |
EBITDA | 145.08M USD |
Net Income Avi to Common (ttm) | 93.17M USD |
Diluted EPS (ttm) | 1.83 |
Quarterly Earnings Growth (yoy) | 7.29% |
Balance Sheet
Total Cash (mrq) | 192.89M USD |
Total Cash Per Share (mrq) | 4 USD |
Total Debt (mrq) | 102.03M USD |
Total Debt/Equity (mrq) | 18.6 USD |
Current Ratio (mrq) | 3.859 |
Book Value Per Share (mrq) | 11.386 |
Cash Flow Statement
Operating Cash Flow (ttm) | 78.8M USD |
Levered Free Cash Flow (ttm) | 48.49M USD |
Profile of Amphastar Pharmaceuticals
Country | United States |
State | CA |
City | Rancho Cucamonga |
Address | 11570 6th Street |
ZIP | 91730 |
Phone | 909 980 9484 |
Website | https://www.amphastar.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 1615 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Q&A For Amphastar Pharmaceuticals Stock
What is a current AMPH stock price?
Amphastar Pharmaceuticals AMPH stock price today per share is 24.07 USD.
How to purchase Amphastar Pharmaceuticals stock?
You can buy AMPH shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amphastar Pharmaceuticals?
The stock symbol or ticker of Amphastar Pharmaceuticals is AMPH.
Which industry does the Amphastar Pharmaceuticals company belong to?
The Amphastar Pharmaceuticals industry is Drug Manufacturers-Specialty & Generic.
How many shares does Amphastar Pharmaceuticals have in circulation?
The max supply of Amphastar Pharmaceuticals shares is 47.5M.
What is Amphastar Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Amphastar Pharmaceuticals PE Ratio is 7.69009540 now.
What was Amphastar Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Amphastar Pharmaceuticals EPS is 3.13 USD over the trailing 12 months.
Which sector does the Amphastar Pharmaceuticals company belong to?
The Amphastar Pharmaceuticals sector is Healthcare.
Amphastar Pharmaceuticals AMPH included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 17166.04 USD — |
+2.74
|
6.86B USD — | 16744.97 USD — | 17174.35 USD — | — - | 6.86B USD — |
NASDAQ Biotechnology Total Retu XNBI | 4534.13 USD — |
+1.81
|
— — | 4437.94 USD — | 4534.31 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2066.02 USD — |
+2.06
|
— — | 2024.76 USD — | 2067.07 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2743.93 USD — |
+1.91
|
— — | 2691.56 USD — | 2748.42 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4190.58 USD — |
+1.81
|
— — | 4101.67 USD — | 4190.75 USD — | — - | — — |
NASDAQ HealthCare IXHC | 930.32 USD — |
+2.05
|
— — | 911.02 USD — | 930.5 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 21012.91 USD — |
+2.74
|
— — | 20497.47 USD — | 21023.08 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 8392.2 USD — |
+2.74
|
— — | 8186.56 USD — | 8396.52 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4126.44 USD — |
+0.05
|
— — | 3927.42 USD — | 4126.44 USD — | — - | — — |
- {{ link.label }} {{link}}